by Plus Therapeutics | Dec 11, 2024 | LM
Reminder: Visit Plus Therapeutics at #SABCS2024 in San Antonio – Booth #1542! Join us at #SABCS2024 in San Antonio, Texas, where Plus Therapeutics will be showcasing its groundbreaking work in targeted radiation therapy for central nervous system cancers including...
by Plus Therapeutics | Dec 9, 2024 | LM
⏯️ 🧠 Now Streaming: Replay the Live Symposium by Plus Therapeutics at #SNO2024 Annual Conference Catch up on the latest advancements in leptomeningeal disease and cancer therapeutics! The live symposium presented by Plus Therapeutics at the #SNO2024 Annual Meeting is...
by Plus Therapeutics | Dec 5, 2024 | LM
🎗️ Now Streaming: A ReSPECT-LM Patient Story | Marlyn, Leptomeningeal Metastases Survivor ⏯️ Watch her inspiring journey on YouTube: A ReSPECT-LM Patient Story: Marlyn’s Journey At the age of 31, while immersed in her Medical Residency for Pediatrics, Dr. Marlyn...
by Plus Therapeutics | Dec 4, 2024 | LM
Exciting News: ReSPECT-LM Leptomeningeal Metastases Clinical Trial to be Showcased at SABCS 2024! Mark your calendars! Plus Therapeutics is thrilled to present groundbreaking data from our ReSPECT-LM Phase 1 clinical trial at the 2024 San Antonio Breast Cancer...
by Plus Therapeutics | Dec 3, 2024 | Uncategorized
Plus Therapeutics Expands Strategic Partnership with Telix IsoTherapeutics for Rhenium-186 Radioisotope Supply BREAKING NEWS: Plus Therapeutics is pleased to announce the expansion of our strategic agreement with Telix IsoTherapeutics Group, a move that strengthens...
Recent Comments